The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.
A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.
Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies
Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.
When it comes to an HIV cure, what do we know now and what are the main areas of focus for future research? Irini Sereti, M.D., reviewed and analyzed the current strategies in cure research, during a presentation at IDWeek 2016 in New Orleans.
On behalf of IFARA, Fred Schaich spoke with François Dabis, M.D., Ph.D., about a study presented at this year's International AIDS Conference on the impact of the "test and treat" strategy on HIV transmission rates.
The results of a "test and treat" pilot project in Swaziland presented at this year's International AIDS Conference were very positive, with a very high uptake of testing and starting treatment, good retention in care and good viral suppression.
Final results of HPTN 052, the watershed randomized trial that positioned antiretroviral therapy (ART) as an HIV prevention strategy, indicate that participants starting ART at a high CD4 count sustained a 93% lower risk of transmitting HIV to sex pa...
On behalf of IFARA, executive producer Fred Schaich spoke with Seema Desai, Ph.D., Peter Hunt, M.D., and Alan Landay, Ph.D., about managing HIV in those over 50 years old.
No Difference in Neuropsychological Test Results Between Early and Delayed Treatment in START Substudy
Neuropsychological test results were similar for those who started antiretroviral therapy immediately and those who waited before starting, according to a substudy in the START study.
People randomized to begin antiretroviral therapy (ART) immediately in the international START trial had steeper declines in bone mineral density (BMD) than people randomised to delayed therapy.